Champions Oncology/$CSBR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Champions Oncology
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
- Ticker
- $CSBR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 214
- Headquarters
- Hackensack, United States
- Website
- www.championsoncology.com
CSBR Metrics
BasicAdvanced
$67M
-
-$0.08
0.40
-
Price and volume
Market cap
$67M
Beta
0.4
52-week high
$8.31
52-week low
$4.59
Average daily volume
8.1K
Financial strength
Current ratio
1.03
Quick ratio
0.959
Long term debt to equity
2.265
Total debt to equity
2.46
Profitability
EBITDA (TTM)
0.402
Gross margin (TTM)
49.82%
Net profit margin (TTM)
-1.87%
Operating margin (TTM)
-1.53%
Effective tax rate (TTM)
-27.24%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-1.82%
Return on equity (TTM)
-28.38%
Valuation
Price to revenue (TTM)
1.092
Price to book
17.09
Price to tangible book (TTM)
18.7
Price to free cash flow (TTM)
-10.795
Free cash flow yield (TTM)
-9.26%
Free cash flow per share (TTM)
-0.443
Growth
Revenue change (TTM)
6.65%
Earnings per share change (TTM)
-138.38%
3-year revenue growth (CAGR)
4.81%
10-year revenue growth (CAGR)
17.56%
3-year earnings per share growth (CAGR)
-47.43%
10-year earnings per share growth (CAGR)
-23.03%
What the Analysts think about CSBR
Majority rating from 1 analysts.
| Month | Buy | Hold | Sell | Analysts | Majority rating |
|---|---|---|---|---|---|
| July 2023 | 2 | 1 | 0 | 3 | Buy |
| August 2023 | 2 | 1 | 0 | 3 | Buy |
| September 2023 | 2 | 1 | 0 | 3 | Buy |
| October 2023 | 2 | 1 | 0 | 3 | Buy |
| November 2023 | 2 | 1 | 0 | 3 | Buy |
| December 2023 | 1 | 0 | 0 | 1 | Buy |
| January 2024 | 1 | 0 | 0 | 1 | Buy |
| February 2024 | 1 | 0 | 0 | 1 | Buy |
| March 2024 | 0 | 1 | 0 | 1 | Hold |
| April 2024 | 0 | 1 | 0 | 1 | Hold |
| May 2024 | 0 | 1 | 0 | 1 | Hold |
| June 2024 | 0 | 1 | 0 | 1 | Hold |
CSBR Financial Performance
Revenues and expenses
CSBR Earnings Performance
Company profitability
Upcoming events
No upcoming events
CSBR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.